Medicine
Beta-lactam therapeutic drug monitoring in critically ill septic patients
Quick fact
In critically ill septic patients, beta-lactam concentrations can be subtherapeutic in up to 50% of patients, even with standard dosing, because of profound changes in fluid balance and kidney function.
Why this is interesting
You are prescribed a standard dose of an antibiotic, but your body metabolizes it differently—so what if the drug never reaches a level high enough to kill the infection? In intensive care, this is a very real problem.
Read the full explanation
Understanding Beta-lactam therapeutic drug monitoring in critically ill septic patients
Beta-lactams are time-dependent antibiotics: their killing effect depends on the time the free drug concentration remains above the minimum inhibitory concentration (MIC) of the pathogen. In a healthy body, standard dosing reliably achieves this. However, in critically ill septic patients, the body is in chaos: fluid shifts into tissues, albumin levels drop, and kidney function can dramatically increase (augmented renal clearance) or fail. These changes make the same dose produce wildly different concentrations in different patients. As a result, some patients end up with concentrations too low to kill bacteria effectively, leading to treatment failure and resistance. Therapeutic drug monitoring solves this by measuring the drug concentration in the patient's blood and adjusting the dose accordingly, personalizing the therapy to each patient's unique body.
A deeper explanation
The mechanism behind TDM for beta-lactams lies in their pharmacokinetics and pharmacodynamics. Beta-lactams exhibit time-dependent killing, meaning the optimal exposure is defined by the percentage of the dosing interval during which the free drug concentration exceeds the MIC (%fT MIC). Typically, a target of 40-100% is recommended. In critically ill patients, altered distribution volume (due to capillary leak and fluid resuscitation) increases the volume of distribution, and altered clearance (either augmented or reduced by renal function) changes elimination. These physiological shifts lead to unpredictable plasma concentrations. By measuring drug levels at specific times (trough and sometimes peak), clinicians can calculate the actual %fT MIC and adjust the dose (change frequency, extend infusion time, or adjust dose amount) to achieve the target. This approach is evidence-based, shown to reduce mortality and improve microbiological cure. Challenges include the need for rapid turnaround of assays and the cost, but the benefit in this vulnerable population is clear. This monitoring transforms beta-lactam therapy from a one-size-fits-all approach into a personalized, precision-medicine intervention.